 | ||||||||||||||||||||||||||||||||
 |
PASSION FOR IDEAS |
|||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||
|
|
LumavitaLumavita is a specialty biopharmaceutical company located in Basel, Switzerland, and dedicated to bringing to market anti-infective drugs for women’s health. Lumavita’s portfolio consists of LMV-601, a first-in-class anti-viral compound (e.g. treatment of Human Papilloma Virus infections) currently in Phase I, and FemiFect® (pentamycin). FemiFect® is an antibiotic for the treatment of vaginitis; unlike currently available therapies, it is adressing the three major causes of this common infection (affecting 10% of women every year).
August 27, 2009 Lumavita AG announces Marketing Authorisation for Pentamycin in Switzerland June 18, 2009 Lumavita AG announces new funding March 24, 2009 Lumavita AG announces receipt of Preliminary Approval for Marketing Authorisation of pentamycin in Switzerland for the treatment of |
|
|
|
|||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||
| partner of the European Tech Tour |  |
"The partners have been very supportive of our approach and stepped in to add value when needed. I would strongly recommend them as investors." Didier Cowling, Founder and CEO, Kuros Biosurgery AG |
||||||||||||||||||||||||||||||
current news
Olivier Valdenaire
Sven Lingjaerde